Categories
Health

Shortly before the application of the vaccine: Biontech presents figures | Free Press

With promising news about its vaccine, Biontech has raised high hopes in the fight against the corona pandemic. Now the Mainz-based company reports how business is going.

Mainz (dpa) – Shortly after the release of encouraging interim results on its corona vaccine, Mainz-based pharmaceutical company Biontech today presents figures for the third quarter.

Additionally, Biontech wants to give “information on operational progress” in a conference call at 2 pm. Biontech and the US pharmaceutical company Pfizer were the first Western manufacturers to publish promising results from a vaccine study that is crucial for approval on Monday. Its vaccine offers more than 90 percent protection against Covid-19, the two companies said. No serious side effects were found.

According to their own information, Biontech and Pfizer intend to apply for approval from the US FDA starting next week. An effective corona vaccine is therefore at hand in Europe and the US Federal Minister of Health Jens Spahn (CDU) said he was assuming a parallel application for approval from the FDA and the European Agency for EMA drugs.

Doctors were surprised by the results of the Biontech and Pfizer investigation, while financial analysts spoke of a possible breakthrough in the fight against the corona pandemic. Shares of the two companies soared on the stock market.

An expedited approval process is applied to corona vaccines due to their particular urgency. Manufacturers of pharmaceutical products can submit individual reports on the quality, safety and efficacy of a preparation to the European Medicines Agency (EMA) even before the full application for approval. In addition to Biontech, the British-Swedish company Astrazeneca has started such a process for its candidate vaccine.

Biontech had been developing the BNT162b2 vaccine in the “Lightspeed” project since mid-January. The phase 3 study, crucial for its approval, began in several countries in late July. As of Monday, more than 43,500 people had received at least one of the two vaccines, which are administered every three weeks. According to the manufacturer, protection by vaccination is achieved one week after the second injection.

Biontech and Pfizer expect to have up to 50 million doses of vaccines available worldwide this year and up to 1.3 billion doses next year. The EU Commission has been negotiating for some time with Biontech and Pfizer on a framework agreement for the delivery of the vaccine to all EU countries.